LONDON — Consuming red meat may increase the risk of colon cancer in women, a new research in Britain has found.
Researchers studied whether beef is associated with risk of colon and rectal cancer compared with poultry, fish or vegetarian diets, according to a research conducted by the University of Leeds, a diet free from red meat significantly reduces the risk of a type of colon cancer in women living in the United Kingdom.
If a woman avoids eating red meat, her risk of colon cancer is significantly reduced, the findings were published Sunday in the International Journal for Cancer said.
When comparing the effects of these diets to cancer development in specific subsites of the colon, they found that those regularly eating red meat compared to a red meat-free diet had higher rates of distal colon cancer – cancer found on the descending section of the colon, where faeces is stored.
Previous studies have suggested that eating lots of red and processed meat increases risk for colorectal cancer but the researchers said there is limited available information about specific dietary patterns and where cancer occurred in the bowel.
Researchers found that regular eaters of red meat had higher rates of distal colon cancer compared with others. The cancer was found on the descending section of the colon, where feces is stored.
Lead author Dr Diego Rada Fernandez de Jauregui said, “The impact of different types of red meat and dietary patterns on cancer locations is one of the biggest challenges in the study of diet and colorectal cancer”.
“Our research is one of the few studies looking at this relationship and while further analysis in a larger study is needed, it could provide valuable information for those with family history of colorectal cancer and those working on prevention.”
The study analysis explored the relationship between the four dietary patterns and colorectal cancer and a further exploratory analysis examined the correlation between diet and colon subsites.
Co-author Janet said, “Our study not only helps shed light on how meat consumption may affect the sections of the colorectum differently, it emphasises the importance of reliable dietary reporting from large groups of people”.
With Agency InputsFollow @gorkhapost
Diabetes drug might ease heart failure risk
A new research has showed that the diabetes drug Farxiga might do double-duty for patients, helping to ward off another killer, heart failure.
According to the findings were published in the New England Journal of Medicine to coincide with their presentation at the annual meeting of the American Heart Association in Chicago, Type 2 diabetics who took Farxiga saw their odds of hospitalization for heart failure drop by 27 percent compared to those who took a placebo.
Farxiga is a type of drug called a SGLT2 inhibitor. The compound is called dapagliflozin.
The study included more than 17,000 type 2 diabetes patients aged 40 and older. Nearly 7,000 had heart disease and more than 10,000 had numerous risk factors for heart disease, Wiviott’s group said.
Patients were randomly assigned to take a dummy placebo pill or 10 milligrams of Farxiga each day.
“When it comes to helping our patients control and manage blood glucose, the ‘how’ appears to be as important [as] the ‘how much,” said study author Dr Stephen Wiviott, a cardiovascular medicine specialist at Brigham and Women’s Hospital in Boston.
“When choosing a therapy, trial results like these can help us make an informed decision about what treatments are not only safe and effective for lowering blood glucose but can also reduce risk of heart and kidney complications,” Wiviott said in a hospital news release.
Taking the drug did not reduce the risk of heart attack, stroke and cardiovascular-related death, the research team noted. However, patients who took the drug did see healthy declines in their blood sugar levels, plus an added bonus: a 27 percent decrease in their risk of hospitalization for heart failure.
Their risk of kidney failure and death from kidney failure also fell, researchers noted.
Two other recent studies of this class of drugs show that they “robustly and consistently improve heart and kidney outcomes in a broad population of patients with diabetes,” Wiviott noted.
With Inputs from HealthDayFollow @gorkhapost